Skip to content

REGENERON PHARMACEUTICALS, INC.

REGN

CIK 0000872589 · Pharmaceutical Preparations · Nasdaq

  • REGENERON PHARMACEUTICALS INC (until 2019-06-19)
← back to feed
Revenue (TTM)
$14.06B
+1.0% YoY Q1 Mar 2026
Net Income (TTM)
$4.39B
+2.1% YoY Q1 Mar 2026
EPS Diluted (TTM)
$40.45
+8.2% YoY Q1 Mar 2026
Gross Margin
97.1%
Q1 Mar 2026
Operating Margin
23.8%
Q1 Mar 2026
Net Margin
31.2%
Q1 Mar 2026
Free Cash Flow (TTM)
$4.23B
Q1 Mar 2026
Cash
$2.96B
Q1 Mar 2026
Total Debt
$3.49B
Q1 Mar 2026
Shares Outstanding
93.96M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings